{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Hemophilia+A&page=2",
    "query": {
      "condition": "Congenital Hemophilia A",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Hemophilia+A&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T09:54:48.345Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01493778",
      "title": "Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Haemophilia A"
      ],
      "interventions": [
        {
          "name": "turoctocog alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "6 Years",
        "sex": "MALE",
        "summary": "0 Years to 6 Years · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2012-09-17",
      "completion_date": "2018-12-05",
      "has_results": true,
      "last_update_posted_date": "2020-11-30",
      "last_synced_at": "2026-07-22T09:54:48.345Z",
      "location_count": 25,
      "location_summary": "Phoenix, Arizona • Long Beach, California • Sacramento, California + 20 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01493778"
    },
    {
      "nct_id": "NCT05987449",
      "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "NXT007",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "59 Years",
        "sex": "MALE",
        "summary": "2 Years to 59 Years · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2023-09-21",
      "completion_date": "2033-12-11",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-07-22T09:54:48.345Z",
      "location_count": 4,
      "location_summary": "Sacramento, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 1 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05987449"
    },
    {
      "nct_id": "NCT01712438",
      "title": "Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Severe Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Human cl rhFVIII",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 110,
      "start_date": "2013-02",
      "completion_date": "2019-12-20",
      "has_results": true,
      "last_update_posted_date": "2021-01-19",
      "last_synced_at": "2026-07-22T09:54:48.345Z",
      "location_count": 3,
      "location_summary": "Sacramento, California • St. Petersburg, Florida • Boston, Massachusetts",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01712438"
    },
    {
      "nct_id": "NCT05568459",
      "title": "A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "Non-Interventional",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "16 Years and older · Male only"
      },
      "enrollment_count": 11,
      "start_date": "2024-01-17",
      "completion_date": "2026-05-21",
      "has_results": false,
      "last_update_posted_date": "2026-03-19",
      "last_synced_at": "2026-07-22T09:54:48.345Z",
      "location_count": 9,
      "location_summary": "Aurora, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05568459"
    },
    {
      "nct_id": "NCT01775618",
      "title": "Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "BAY94-9027",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "12 Years",
        "sex": "MALE",
        "summary": "Up to 12 Years · Male only"
      },
      "enrollment_count": 73,
      "start_date": "2013-05-29",
      "completion_date": "2020-02-19",
      "has_results": false,
      "last_update_posted_date": "2020-08-21",
      "last_synced_at": "2026-07-22T09:54:48.345Z",
      "location_count": 7,
      "location_summary": "Sacramento, California • Pensacola, Florida • Cincinnati, Ohio + 4 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01775618"
    },
    {
      "nct_id": "NCT04621916",
      "title": "Preventing Inhibitor Recurrence Indefinitely",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hemophilia A",
        "Immune Tolerance"
      ],
      "interventions": [
        {
          "name": "FVIII",
          "type": "DRUG"
        },
        {
          "name": "Emicizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "12 Years",
        "sex": "MALE",
        "summary": "0 Years to 12 Years · Male only"
      },
      "enrollment_count": 52,
      "start_date": "2020-09-21",
      "completion_date": "2025-04-20",
      "has_results": false,
      "last_update_posted_date": "2023-10-05",
      "last_synced_at": "2026-07-22T09:54:48.345Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04621916"
    },
    {
      "nct_id": "NCT00243386",
      "title": "Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Antihemophilic factor, recombinant, manufactured protein-free",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "7 Years to 65 Years"
      },
      "enrollment_count": 82,
      "start_date": "2006-01-04",
      "completion_date": "2010-06-16",
      "has_results": true,
      "last_update_posted_date": "2021-05-19",
      "last_synced_at": "2026-07-22T09:54:48.345Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00243386"
    },
    {
      "nct_id": "NCT00357656",
      "title": "Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Recombinant Protein-Free Factor VIII (rAHF-PFM)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 85,
      "start_date": "2006-05-29",
      "completion_date": "2015-12-09",
      "has_results": true,
      "last_update_posted_date": "2021-05-19",
      "last_synced_at": "2026-07-22T09:54:48.345Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00357656"
    },
    {
      "nct_id": "NCT00629837",
      "title": "Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant Factor VIII (Kogenate FS, BAY14-2222)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "60 Years",
        "sex": "MALE",
        "summary": "12 Years to 60 Years · Male only"
      },
      "enrollment_count": 27,
      "start_date": "2005-09",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2014-11-18",
      "last_synced_at": "2026-07-22T09:54:48.345Z",
      "location_count": 2,
      "location_summary": "Davis, California • Orange, California",
      "locations": [
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00629837"
    },
    {
      "nct_id": "NCT05248594",
      "title": "Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "HEMLIBRA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Montefiore Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "36 Months",
        "sex": "ALL",
        "summary": "Up to 36 Months"
      },
      "enrollment_count": 71,
      "start_date": "2024-08-01",
      "completion_date": "2025-07-18",
      "has_results": false,
      "last_update_posted_date": "2025-09-08",
      "last_synced_at": "2026-07-22T09:54:48.345Z",
      "location_count": 10,
      "location_summary": "Hartford, Connecticut • New Haven, Connecticut • Lebanon, New Hampshire + 7 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Newark",
          "state": "New Jersey"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05248594"
    }
  ]
}